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Graft-versus-host reaction was first described following 
splenocyte transplantationl and was correctly attributed to recog-
nition of the host by immunologically competent cells of the graft. 
Soon, the same phenomenon was recognized in recipients of organs 
that are rich in lymphoid tissue2 and was demonstrated after parent 
to offspring Fl hybrid intestinal transplantation in rats. 3 An increas-
ing frequency of graft-versus-host-disease (GVHD) has been ob-
served after transplantation of other organs, including the hu-
man liver4 . l2 
In this report, we describe reversal of GVHD in a recipient of a 
combined liver-bone marrow transplant by infusion of stored 
autologous bone marrow cells. 
GaseReport 
A 56-year-old man with a gastric leiomyosarcoma with liver 
metastases underwent upper abdominal exenteration and orthotopic 
liver allotransplantation on July 16, 1992. Shortly before operation, 
the patient was treated with a single dose of 550 rads thoraco-
abdominal lymphoid irradiation (Til). Immediately after opera-
tion, 19 x 109 donor bone marrow cells harvested from 10 vertebral 
bodies were infused IV through a central line. Postoperative 
immunosuppression was with FK 506 and prednisone. 
A skin rash developed within the first postoperative week. The 
rash, that was initially mild and confined to the areas exposed to the 
preoperative Til, progressively worsened and the diagnosis of 
GVHD was made on a skin biopsy 15 days following surgery. 
Histologic examination of the skin biopsy revealed a mild, pre-
dominantly T lymphocyte infiltrate localized to the upper dermis 
that was associated with focal exocytosis and spongiosis and with 
occasional kerarinocyte necrosis. The infiltrating cells were recog-
nized as of donor HLA type by immunostaining. A second biopsy 
on postoperative day 21 revealed more florid changes that included 
acantholysis and focal cleft formation. A third biopsy one week later 
showed continued damage to keratinocytes and adnexal cells, with 
an inflammatory infiltrate of the upper dermis that was signifl-
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cantly more conspicuous than in prior biopsies. Immunoperoxidase 
stains showed the cells to be T lymphocytes of donor origin. 
The skin involvement spread to more than 80% of the body 
surface, including the palms, soles and face. The progression of 
GVHD was not altered by increases or decreases of FK 506 or 
prednisone. Throughout this time, 22 to 34% of the circulating 
lymphocytes were donor phenotype, as determined by flow cyrometry 
using appropriate anti-HLA class I monoclonal antibodies. 
On the 42nd and 43rd posroperative days, 2.83 X 108 autolo-
gous bone marrow cells/kilograms were infused. The skin rash 
promptly improved and completely resolved within two weeks after 
the autologous cell infusion with a reduction of circulating donor 
lymphocytes which never again exceeded 10% of the total and was 
in the 3% range on postoperative day 96. The patient who had been 
gravely ill was restored to a sense of well being and was discharged 
three weeks following the autologous bone marrow infusion. 
Donor-specific alloreactivity was assessed in mixed lymphocyte 
reaction (MLR) and in cell-mediated lympholysis (CML) 
pretransplant, during the first month postsurgery and following 
autologous bone marrow infusion. Prerransplant recipient periph-
eral blood exhibited proliferative responses to donor or third party 
irradiated spleen cells. During the first postoperative month, his 
MLR responses to both donor and third party were significantly 
suppressed. However, following infusion of the autologous mar-
row the MLR responses were reestablished, and the patient 
showed donor-specific CML activity. Restoration of immuno-
competence towards the donor coincided with the clinical reso-
lution of the GVHD. 
Cotnment 
GVHD in intestinal or hepatic recipients cannot be defined by 
conventional criteria because the donor origin of the transplanted 
organs prevents them from becoming a target of GVHD while 
exposing them to the risk of rejection. Consequently, the most 
unequivocal finding may be a skin rash such as that observed in 
approximately 5% of our liver allograft recipients. For years, these 
dermatologic manifestations were attributed to a drug or to an 
allergic reaction, until it was realized that systemic chimerism 
occurs after all successful transplamations, creating the possibility 
ofGVHD in every case.' 2 
Storage of autologous bone marrow could represent a safety net 
in pilot trials of bone marrow-organ transplantation, until the risk 
for severe GVHD is better understood or until alternative ap-
proaches are developed to prevent GVHD, such as a bone marrow 
component approach, or by UVB irradiation of the allogeneic bone 
marrow (Mark Hardy, this issue). 
Understanding the difference between the autologous naive cells 
that had been in storage and the immunocytes in the patient that 
had become defenseless against attack by cohabitation for six weeks 
with donor cells would go far in explaining the changes brought 
about by chimerism. The therapeuric rescue was reminiscent of a 
tolerance breaking experiment mentioned in the classic article of 
Billingham, Brent, and Medawar. I3 However, the incompleteness 
of the effect in our patient allowed control of the GVHD without 
rejection of the liver allograft. 
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